Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBT (2016 - 2025)

Historic EBT for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$1.1 million.

  • Lifecore Biomedical, Inc. \De\'s EBT rose 8440.43% to -$1.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$38.7 million, marking a year-over-year decrease of 50649.57%. This contributed to the annual value of -$38.7 million for FY2025, which is 50649.57% down from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s EBT stood at -$1.1 million, which was up 8440.43% from -$14.8 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year EBT high stood at $15.0 million for Q1 2024, and its period low was -$36.8 million during Q2 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median EBT value was -$6.9 million (recorded in 2022), while the average stood at -$6.6 million.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s EBT tumbled by 128565.4% in 2021 and then soared by 25414.81% in 2023.
  • Lifecore Biomedical, Inc. \De\'s EBT (Quarter) stood at $1.3 million in 2021, then tumbled by 823.03% to -$9.2 million in 2022, then skyrocketed by 254.15% to $14.2 million in 2023, then plummeted by 146.05% to -$6.5 million in 2024, then surged by 82.94% to -$1.1 million in 2025.
  • Its EBT was -$1.1 million in Q2 2025, compared to -$14.8 million in Q1 2025 and -$6.5 million in Q4 2024.